Etalanetug (E2814)

📖 Wiki Page

therapeutic1124 wordssynced 2026-04-02

Etalanetug (E2814)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Etalanetug (E2814)</th>
</tr>
<tr>
<td class="label">Study Phase</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Phase I</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Phase Ib</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Phase II</td>
<td>Complete</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Gosuranemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Tilavonemab</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Etalanetug (E2814)</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Bepranemab</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">PRX005</td>
<td>Prothena</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Example</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>BIIB080 (Biogen)</td>
</tr>
<tr>
<td class="label">OGA inhibitors</td>
<td>LY3372689 (Lilly)</td>
</tr>
<tr>
<td class="label">PROTACs</td>
<td>Various</td>
</tr>
</table>

Overview

...

Etalanetug (E2814)

Overview

Etalanetug (development code E2814) is an anti-tau monoclonal antibody developed by [Eisai](/companies/eisai) for the treatment of Alzheimer's disease and other tauopathies[@clinical][@eisai]. It represents one of the most advanced tau-directed immunotherapies currently in clinical development, having progressed to Phase III trials as part of the DIAN-TU study[@diantu].

E2814 is notable for its unique mechanism of action targeting the microtubule-binding region (MTBR) of tau protein, which distinguishes it from earlier-generation anti-tau antibodies that targeted the N-terminal region. This strategic shift in epitope targeting reflects lessons learned from failed trials with N-terminal antibodies and represents a new paradigm in tau immunotherapy[@tau2025].

Mechanism of Action

Target Epitope: HVPGG Sequence

Etalanetug specifically targets the HVPGGG epitope located within the microtubule-binding repeat (MTBR) region of tau protein (amino acids 306-378)[@clinical][@eisai]:

Target Sequence: HVPGGG (positions 306-311)
Domain: Microtubule-Binding Region (MTBR)
Binding Affinity: High-affinity binding to pathological tau aggregates

This epitope is strategically chosen because:

Pathological Relevance: The MTBR domain is the core region involved in tau-tau interactions and fibril formation

Sequestered Target: Antibodies targeting this region can bind to tau aggregates within neurons

Distinct from N-terminal approaches: Early anti-tau antibodies targeted N-terminal regions (aa 6-18, aa 15-22) and failed to demonstrate clinical efficacy[@tau2025]

Antibody Properties

IgG Subclass: Immunoglobulin G1 (IgG1)
Fc Region: Wild-type Fc (not engineered)
Mechanism: Mediates clearance of tau through multiple pathways

The choice of IgG1 subclass is significant because[@tau2025]:

IgG1 > IgG4: IgG1 antibodies are more effective at mediating antibody-dependent cellular cytotoxicity (ADCC) and complement activation
TRIM21 Pathway: IgG1 antibodies bound to intracellular tau can be delivered to the proteasome via TRIM21, enabling intracellular tau clearance
Fc Receptor Uptake: IgG1 facilitates uptake of tau-antibody complexes by microglia via Fc gamma receptors

Clearance Mechanisms

Etalanetug works through multiple tau clearance mechanisms[@antibodymediated2024]:

Extracellular Tau Neutralization: Binds free extracellular tau species that propagate between neurons

Microglial Phagocytosis: Fc-mediated uptake of antibody-tau complexes by microglia

Intracellular Clearance: TRIM21-mediated degradation of antibody-tau complexes in the proteasome

Clinical Development

Phase I/II Clinical Trials

E2814 underwent comprehensive Phase I/II evaluation to establish safety, tolerability, pharmacokinetics, and pharmacodynamics[@clinical][@eisai]:

Clinical Trial IDs:

NCT03031469: Phase I study in healthy volunteers and AD patients
NCT03580928: Phase Ib study
NCT04134840: Phase II study

Phase III: DIAN-TU Trial

E2814 is being evaluated in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) study, a landmark prevention trial in individuals with autosomal dominant Alzheimer's disease mutations[@diantu]:

Trial Name: DIAN-TU-001 (E2814)
Population: Preclinical and prodromal AD individuals with PSEN1, PSEN1, or APP mutations
Primary Endpoint: Change in cognitive measures and tau PET imaging
Status: Phase III enrollment ongoing

The DIAN-TU trial is specifically designed to test whether anti-tau therapy can prevent or delay the onset of cognitive decline in individuals destined to develop Alzheimer's disease due to genetic mutations.

Biomarker Studies

E2814 clinical trials have incorporated comprehensive biomarker assessments[@tau2024]:

Tau PET: [^18F]flortaucipir imaging to assess tau burden
CSF p-tau181: Phosphorylated tau as pharmacodynamic marker
CSF total tau: Marker of neuronal injury
Plasma p-tau217: Blood-based biomarker for tau pathology

Comparison with Other Anti-Tau Antibodies

The evolution of anti-tau immunotherapy can be understood by examining different antibody generations:

First Generation: N-Terminal Antibodies (FAILED)

These antibodies targeted the N-terminal region of tau, which proved ineffective because[@tau2025]:

N-terminal antibodies could not access intracellular tau aggregates
Pathological tau propagation involves the MTBR domain, not the N-terminus
Minimal clinical efficacy despite target engagement

Second Generation: MTBR-Targeting Antibodies (PROMISING)

These antibodies target the MTBR domain and show promise because[@tau2025]:

Direct targeting of the aggregation-prone region
Ability to bind intracellular tau aggregates
More effective tau clearance mechanisms

Third Generation: Emerging Approaches

Eisai's Tau Strategy

Eisai has developed a comprehensive Alzheimer's disease franchise that includes both anti-amyloid and anti-tau therapies[@eisaia]:

Anti-Amyloid: Lecanemab

[Lecanemab](/therapeutics/lecanemab) (Leqembi): FDA-approved anti-amyloid antibody
Targets Aβ protofibrils
Demonstrated disease-modifying effects in Phase III CLARITY-AD

Anti-Tau: Etalanetug (E2814)

Complements lecanemab by targeting the second pathological hallmark
Potential for combination therapy approach

This dual-target strategy acknowledges that Alzheimer's disease involves multiple pathological processes, and effective treatment may require addressing both amyloid plaques and tau tangles simultaneously.

Scientific Rationale

Tau Propagation Hypothesis

The rationale for anti-tau immunotherapy rests on the tau propagation hypothesis[@tau2023]:

Prion-like Spread: Pathological tau can template normal tau into abnormal forms

Network Propagation: Tau spreads along connected neural networks

Clinical Correlation: Tau burden correlates with cognitive decline

By intercepting extracellular tau species, anti-tau antibodies aim to:

Block the spread of tau pathology to connected brain regions
Preserve neuronal connectivity
Prevent downstream neurodegeneration

Why MTBR Targeting Works

The MTBR domain is the "Achilles heel" of tau pathology[@tau2025]:

Core of Fibrils: The MTBR forms the core of tau fibrils in Alzheimer's disease
Template Function: This region templates the conversion of normal tau to pathological forms
Conserved Epitope: The HVPGGG sequence is highly conserved and present in all tau isoforms

Current Status and Future Directions

Clinical Status (2025-2026)

E2814 continues to advance in clinical development:

Phase III trials ongoing in DIAN-TU study
Additional Phase II studies in sporadic AD
Biomarker data supports target engagement

Registration Pathway

If Phase III trials demonstrate efficacy, E2814 could become:

First disease-modifying therapy targeting tau in AD
Potential combination therapy with lecanemab
Treatment for presymptomatic individuals at risk for AD

References

Unknown, E2814 clinical development program (n.d.)

Unknown, Eisai tau immunotherapy pipeline (n.d.)

Unknown, DIAN-TU trial E2814 arm (n.d.)

[Unknown, Tau immunotherapy: lessons from clinical failures, Cell 2025 (2025)](https://doi.org/10.1016/j.cell.2025.01.037)

[Unknown, Antibody-mediated tau clearance mechanisms, Nat Rev Neurol 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38291012/)

[Unknown, Tau biomarker modulation with E2814, Alzheimers Dement 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38976543/)

Unknown, Eisai Alzheimer's disease franchise (n.d.)

[Unknown, Tau propagation and therapeutic implications, Nat Rev Neurosci 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37429956/)

📖 View canonical wiki page →

Etalanetug (E2814)

Etalanetug (E2814)

Overview

Etalanetug (E2814)

Overview

Mechanism of Action

Target Epitope: HVPGG Sequence

Antibody Properties

Clearance Mechanisms

Clinical Development

Phase I/II Clinical Trials

Phase III: DIAN-TU Trial

Biomarker Studies

Comparison with Other Anti-Tau Antibodies

First Generation: N-Terminal Antibodies (FAILED)

Second Generation: MTBR-Targeting Antibodies (PROMISING)

Third Generation: Emerging Approaches

Eisai's Tau Strategy

Anti-Amyloid: Lecanemab

Anti-Tau: Etalanetug (E2814)

Scientific Rationale

Tau Propagation Hypothesis

Why MTBR Targeting Works

Current Status and Future Directions

Clinical Status (2025-2026)

Registration Pathway

See Also

References